{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fuchs SP"],"funding":["U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)"],"pagination":["8906"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12504686"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Long-term delivery of broadly neutralizing antibodies (bnAbs) using adeno-associated virus (AAV) vector is a promising approach for both the prevention and treatment of HIV infection. However, host anti-drug antibody (ADA) responses severely limit the continuous delivery of these anti-HIV bnAbs and have been the most important obstacle for development of this approach for widespread human use. Transient treatment with the immunomodulatory agent rapamycin (sirolimus) allows for continuous long-term delivery of the anti-HIV bnAb 3BNC117 in immunocompetent mice in the absence of detectable ADAs. Use of the agent in monkeys results in 12 of 15 successful deliveries of the bnAbs 3BNC117, 10-1074, and PGT145 following drug cessation across all animals. The results of this 5-monkey trial lend str"],"journal":["Nature communications"],"pubmed_title":["Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies."],"pmcid":["PMC12504686"],"funding_grant_id":["U19AI149646"],"pubmed_authors":["Martinez-Navio JM","Dudley DM","Zhen A","Zabizhin R","Cook E","Gao G","Weisgrau KL","Mondragon PG","Wang L","Furlott J","Coonen J","Tomer S","Fuchs SP","Alexander E","Xie J","Termini JM","Desrosiers RC"],"additional_accession":[]},"is_claimable":false,"name":"Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies.","description":"Long-term delivery of broadly neutralizing antibodies (bnAbs) using adeno-associated virus (AAV) vector is a promising approach for both the prevention and treatment of HIV infection. However, host anti-drug antibody (ADA) responses severely limit the continuous delivery of these anti-HIV bnAbs and have been the most important obstacle for development of this approach for widespread human use. Transient treatment with the immunomodulatory agent rapamycin (sirolimus) allows for continuous long-term delivery of the anti-HIV bnAb 3BNC117 in immunocompetent mice in the absence of detectable ADAs. Use of the agent in monkeys results in 12 of 15 successful deliveries of the bnAbs 3BNC117, 10-1074, and PGT145 following drug cessation across all animals. The results of this 5-monkey trial lend str","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:24:10.72Z","creation":"2026-05-06T03:13:24.004Z"},"accession":"S-EPMC12504686","cross_references":{"pubmed":["41057323"],"doi":["10.1038/s41467-025-63970-6"]}}